<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00510432</url>
  </required_header>
  <id_info>
    <org_study_id>16/07</org_study_id>
    <nct_id>NCT00510432</nct_id>
  </id_info>
  <brief_title>Incidence and Nature of Heparin-induced Skin Lesions in Medical Patients</brief_title>
  <official_title>Inzidenz Und Art Heparin-induzierter Hautveränderungen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johann Wolfgang Goethe University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johann Wolfgang Goethe University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An increased number of patients with heparin-induced skin lesions is reported in the
      literature. Heparin-induced skin lesions may result from either occlusion of cutaneous
      vessels in patients suffering from autoimmune HIT or from a type IV allergic reaction
      (delayed type hypersensitivity (DTH) response). However, the incidence and nature of
      heparin-induced skin lesions has not been determined in a prospective investigation.

      To address this open issue is the goal of this ongoing, so far monocenter, clinical
      investigation.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2007</start_date>
  <completion_date type="Anticipated">January 2009</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Allergy</condition>
  <arm_group>
    <arm_group_label>s.c. anticoagulant therapy</arm_group_label>
    <description>All patients with s.c. anticoagulant therapy (UFH, LMWH, heparinoids, fondaparinux)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients receiving s.c. anti-coagulation
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &gt; 18 Y.

          -  s.c. anticoagulant therapy &gt;6 days

        Exclusion Criteria:

          -  history of HIT

          -  history of DTH to heparin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ralf J Ludwig, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Dermatology - Clinic of the Johann Wolfgang Goethe University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ralf J Ludwig, MD</last_name>
    <phone>+49-69-6301-</phone>
    <phone_ext>6162</phone_ext>
    <email>r.ludwig@em.uni-frankfurt.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wolf-Henning Boehncke, Professor</last_name>
    <phone>+49-69-6301-</phone>
    <phone_ext>5143</phone_ext>
    <email>boehncke@em.uni-frankfurt.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Dermatology - Clinic of the Johann Wolfgang Goethe University</name>
      <address>
        <city>Frankfurt am Main</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ralf J Ludwig, MD</last_name>
      <phone>+49-69-6301-</phone>
      <phone_ext>6162</phone_ext>
      <email>r.ludwig@em.uni-frankfurt.de</email>
    </contact>
    <contact_backup>
      <last_name>Marc Schindewolf, MD</last_name>
      <phone>+49-69-6301-</phone>
      <phone_ext>5444</phone_ext>
      <email>marcschindewolf@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ralf J Ludwig, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc Schindewolf, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Svantje Schwaner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Edelgard Lindhoff-Last, PD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wolf-Henning Boehncke, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.kgu.de/zdv</url>
    <description>Homepage of the Department of Dermatology with contact persons in the dermatology department listed (site in German)</description>
  </link>
  <link>
    <url>http://www.gefaesszentrum-frankfurt.de</url>
    <description>Homepage of the Department of Internal Medicine (Angiology) with contact persons in the angiology department listed (site in German)</description>
  </link>
  <reference>
    <citation>Jappe U. Allergy to heparins and anticoagulants with a similar pharmacological profile: an update. Blood Coagul Fibrinolysis. 2006 Nov;17(8):605-13. Review.</citation>
    <PMID>17102645</PMID>
  </reference>
  <reference>
    <citation>Ludwig RJ, Schindewolf M, Utikal J, Lindhoff-Last E, Boehncke WH. Management of cutaneous type IV hypersensitivity reactions induced by heparin. Thromb Haemost. 2006 Nov;96(5):611-7. Review.</citation>
    <PMID>17080218</PMID>
  </reference>
  <reference>
    <citation>Bircher AJ, Harr T, Hohenstein L, Tsakiris DA. Hypersensitivity reactions to anticoagulant drugs: diagnosis and management options. Allergy. 2006 Dec;61(12):1432-40. Review.</citation>
    <PMID>17073874</PMID>
  </reference>
  <reference>
    <citation>Ludwig RJ, Schindewolf M, Alban S, Kaufmann R, Lindhoff-Last E, Boehncke WH. Molecular weight determines the frequency of delayed type hypersensitivity reactions to heparin and synthetic oligosaccharides. Thromb Haemost. 2005 Dec;94(6):1265-9.</citation>
    <PMID>16411404</PMID>
  </reference>
  <reference>
    <citation>Warkentin TE, Roberts RS, Hirsh J, Kelton JG. Heparin-induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome: a nested cohort study. Chest. 2005 May;127(5):1857-61.</citation>
    <PMID>15888871</PMID>
  </reference>
  <reference>
    <citation>Maetzke J, Hinrichs R, Schneider LA, Scharffetter-Kochanek K. Unexpected delayed-type hypersensitivity skin reactions to the ultra-low-molecular-weight heparin fondaparinux. Allergy. 2005 Mar;60(3):413-5.</citation>
    <PMID>15679737</PMID>
  </reference>
  <reference>
    <citation>Gaigl Z, Pfeuffer P, Raith P, Bröcker EB, Trautmann A. Tolerance to intravenous heparin in patients with delayed-type hypersensitivity to heparins: a prospective study. Br J Haematol. 2005 Feb;128(3):389-92.</citation>
    <PMID>15667543</PMID>
  </reference>
  <reference>
    <citation>Hirsch K, Ludwig RJ, Lindhoff-Last E, Kaufmann R, Boehncke WH. Intolerance of fondaparinux in a patient allergic to heparins. Contact Dermatitis. 2004 Jun;50(6):383-4.</citation>
    <PMID>15274739</PMID>
  </reference>
  <reference>
    <citation>Koch P. Delayed-type hypersensitivity skin reactions due to heparins and heparinoids. Tolerance of recombinant hirudins and of the new synthetic anticoagulant fondaparinux. Contact Dermatitis. 2003 Dec;49(6):276-80.</citation>
    <PMID>15025697</PMID>
  </reference>
  <reference>
    <citation>Ludwig RJ, Beier C, Lindhoff-Last E, Kaufmann R, Boehncke WH. Tolerance of fondaparinux in a patient allergic to heparins and other glycosaminoglycans. Contact Dermatitis. 2003 Sep;49(3):158-9.</citation>
    <PMID>14678213</PMID>
  </reference>
  <reference>
    <citation>Warkentin TE, Sheppard JA, Sigouin CS, Kohlmann T, Eichler P, Greinacher A. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood. 2006 Nov 1;108(9):2937-41. Epub 2006 Jul 20.</citation>
    <PMID>16857993</PMID>
  </reference>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 1, 2007</study_first_submitted>
  <study_first_submitted_qc>August 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2007</study_first_posted>
  <last_update_submitted>August 18, 2009</last_update_submitted>
  <last_update_submitted_qc>August 18, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr. Marc Schindewolf</name_title>
    <organization>Johann Wolfgang Goethe University Hospitals</organization>
  </responsible_party>
  <keyword>heparin</keyword>
  <keyword>heparin-induced thrombocytopenia</keyword>
  <keyword>HIT</keyword>
  <keyword>allergy</keyword>
  <keyword>skin</keyword>
  <keyword>dermatology</keyword>
  <keyword>DTH</keyword>
  <keyword>delayed-type hypersensitivity</keyword>
  <keyword>histology</keyword>
  <keyword>Patients receiving sc heparin therapy</keyword>
  <keyword>Age over 18 years</keyword>
  <keyword>Recruitment will stop when 20 patients with skin lesions are included</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Anticoagulants</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

